國家衛生研究院 NHRI:
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 906793      Online Users : 926
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version

    Collection

    Periodical Articles [327/330]
    Books/Book Section [1/1]
    Conference Papers/Meeting Abstract [115/179]

    Community Statistics


    Item counts issued in 3 years:74(14.51%)
    Items With Fulltext:443(86.86%)

    Download counts of the item
    Download times greater than 0:443(100.00%)
    Download times greater than 100:426(96.16%)
    Total Bitstream Download Counts:178127(3.32%)

    Last Update: 2024-12-01 08:26

    Top Upload

    Loading...

    Top Download

    Loading...

    RSS Feed RSS Feed
    Jump to a point in the index:
    Or type in a year:
    Ordering With Most Recent First Show Oldest First

    Showing items 51-75 of 510. (21 Page(s) Totally)
    << < 1 2 3 4 5 6 7 8 9 10 > >>
    View [10|25|50] records per page

    DateTitleRelation
    2022-07 Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors Annals of Oncology. 2022 Jul;33(Suppl. 6):S484.
    2022-07 A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer Annals of Oncology. 2022 Jul;33(Suppl. 6):S478.
    2022-06-22 Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study Frontiers in Oncology. 2022 Jun 22;12:Article number 800842.
    2022-06-02 Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma Journal of Hepatocellular Carcinoma. 2022 Jun 2;9:517-536.
    2022-06 Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin Journal of Hepato-Biliary-Pancreatic Sciences. 2022 Jun;54(5):607-612.
    2022-06 Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4120.
    2022-06 Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4009.
    2022-05-15 Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: A single institution experience American Journal of Cancer Research. 2022 May 15;12(5):2189-2202.
    2022-05 Transcriptional suppression of Dicer by HOXB-AS3/EZH2 complex dictates sorafenib resistance and cancer stemness Cancer Science. 2022 May;113(5):1601-1612.
    2022-04-18 The trinity: Interplay among cancer cells, fibroblasts, and immune cells in pancreatic cancer and implication of CD8(+) T cell-orientated therapy Biomedicines. 2022 Apr 18;10(4):Article number 926.
    2022-04-15 The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan American Journal of Cancer Research. 2022 Apr 15;12(4):1884-1898.
    2022-04-11 Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment Journal of Experimental and Clinical Cancer Research. 2022 Apr 11;41:Article number 137.
    2022-04 A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study British Journal of Cancer. 2022 Apr;126(7):1018-1026.
    2022-04 Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials Journal for Immunotherapy of Cancer. 2022 Apr;10(4):Article number e004273.
    2022-02-24 Semaphorin 6C suppresses proliferation of pancreatic cancer cells via inhibition of the AKT/GSK3/beta-catenin/cyclin D1 pathway International Journal of Molecular Sciences. 2022 Feb 24;23(5):Article number 2608.
    2022-02-16 Current status of the spectrum and therapeutics of helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma Cancers. 2022 Feb 16;14(4):Article number 1005.
    2022-02-15 Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1 American Journal of Cancer Research. 2022 Feb 15;12(2):713-728.
    2022-02-01 A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):378.
    2022-02-01 A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):550.
    2022-02 Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010) International Journal of Urology. 2022 Feb;29(2):121-127.
    2022-02 Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr Lancet Oncology. 2022 Feb;23(2):234-247.
    2022-02 Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors Journal of Clinical Oncology. 2022 Feb;40(4, Suppl.):660.
    2022-01 Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation Journal of the Formosan Medical Association. 2022 Jan;121(1 Pt 1):170-180.
    2022-01 Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study Gastric Cancer. 2022 Jan;25(1):207-217.
    2021-11-30 Survival outcomes of management in metastatic gastric adenocarcinoma patients Scientific Reports. 2021 Nov 30;11:Article number 23142.

    Showing items 51-75 of 510. (21 Page(s) Totally)
    << < 1 2 3 4 5 6 7 8 9 10 > >>
    View [10|25|50] records per page

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback